CN Patent

CN121712505A — 使用因子b抑制剂的方法

Assigned to Novartis AG · Expires 2026-03-20 · 0y expired

What this patent protects

本文描述了用因子B抑制剂伊普可泮或其药学上可接受的盐或水合物治疗gMG（全身性重症肌无力）的方法。

USPTO Abstract

本文描述了用因子B抑制剂伊普可泮或其药学上可接受的盐或水合物治疗gMG（全身性重症肌无力）的方法。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN121712505A
Jurisdiction: CN
Classification: —
Expires: 2026-03-20
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.